Download PDF
Thromb Haemost 2019; 119(06): 871-881
DOI: 10.1055/s-0039-1683442
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

The Disulfide Bond between Cys22 and Cys27 in the Protease Domain Modulate Clotting Activity of Coagulation Factor X

Fang Li   *
1   State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
,
Changming Chen   *
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Si-Ying Qu
1   State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
,
Ming-Zhu Zhao
3   Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai, China
,
Xiaoling Xie
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Xi Wu
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Lei Li
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Xuefeng Wang
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4   Faculty of Laboratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Qiulan Ding
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Qin Xu 
1   State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
,
Dong-Qing Wei
1   State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
,
Wenman Wu
2   Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4   Faculty of Laboratory Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5   Collabortive Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
› Author Affiliations Funding This study was supported by the National Natural Science Foundation of China (81570115, 31770772, 61832019 and 61503244), the Key Research Area Grant 2016YFA0501703 of the Ministry of Science and Technology of China, and Joint Research Funds for Translational Medicine at Shanghai Jiao Tong University (ZH2018ZDA06).
Further Information

Publication History

10 October 2018

30 January 2019

Publication Date:
27 March 2019 (online)

    Permissions and Reprints

Abstract

The Cys22-Cys27 disulfide bond of factor X (FX) protease domain is not conserved among coagulation factors and its contribution to the physiological haemostasis and implication in the pathogenesis of haemostatic and thrombotic disorders remain to be elucidated. Mutation p.Cys27Ser was identified in a pedigree of congenital FX deficiency and fluorescence labelling study of transiently transfected HEK293 cells showed accumulation of FX p.Cys27Ser within cell, indicating incompetent secretion partially responsible for the FX deficiency. The clotting activity of FX p.Cys27Ser was decreased to about 90% of wild-type, while amidolytic and pro-thrombinase activities (kcat/Km) determined with recombinant FXa mutant were 1.33- and 4.77-fold lower. Molecular dynamic simulations revealed no major change in global structure between FXa p.Cys27Ser and wild-type FXa; however, without the Cys22-Cys27 disulfide bond, the insertion of newly formed N terminal of catalytic domain after the activation cleavage is hindered, perturbing the conformation transition from zymogen to enzyme. The crystal structure of FXa shows that this disulfide bond is solvent accessible, indicating that its stability might be subject to the oxidation/reduction balance. As demonstrated with FX p.Cys27Ser here, Cys22-Cys27 disulfide bond may modulate FX clotting activity, with reduced FX pertaining less pro-coagulant activity.

Keywords

coagulation factor X - Cys27 - disulfide bond - oxidation/reduction balance - molecular dynamic simulations

Authors' Contributions

F.L. performed molecular dynamic simulations and analysis; C.C. performed protein expression collection and purification and enzyme kinetical analysis; S.Q. and M.Z. contributed to discussion and manuscript revision of MD results; X.W. performed clinical data acquisition; X.X. and L.L. performed phenotype and genetic analysis; X.W. and Q.D. supervised studies conducted in Ruijin Hospital, Shanghai Jiao Tong University; D.W. supervised studies in School of Life Sciences and Biotechnology, Shanghai Jiao Tong university; and Q.X. and W.W. designed experiments, analysed the data and wrote the manuscript. All authors approved the final version of this manuscript.


* Fang Li and Changming Chen equally contributed to this work.


Supplementary Material

 

  • References

  • 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30 (43) 10363-10370
    CrossrefPubMedGoogle Scholar
  • 2 Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16 (02) 97-110
    CrossrefPubMedGoogle Scholar
  • 3 Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35 (04) 407-415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001; 85 (06) 1011-1117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Davie E, Ichinose A, Leytus S. Structural features of the proteins participating in blood coagulation and fibrinolysis. Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1986: 509-514
    Google Scholar
  • 6 Ding Q, Shen Y, Yang L, Wang X, Rezaie AR. The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade. Thromb Haemost 2013; 110 (01) 53-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Lu Q, Yang L, Manithody C, Wang X, Rezaie AR. Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene. Thromb Res 2014; 134 (05) 1103-1109
    CrossrefPubMedGoogle Scholar
  • 8 Roehrig S, Straub A, Pohlmann J. , et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48 (19) 5900-5908
    CrossrefPubMedGoogle Scholar
  • 9 Pettersen EF, Goddard TD, Huang CC. , et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25 (13) 1605-1612
    CrossrefPubMedGoogle Scholar
  • 10 Best RB, Zhu X, Shim J. , et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ(1) and χ(2) dihedral angles. J Chem Theory Comput 2012; 8 (09) 3257-3273
    CrossrefPubMedGoogle Scholar
  • 11 Abraham MJ, Murtola T, Schulz R. , et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015; 1–2: 19-25
    PubMedGoogle Scholar
  • 12 Hess B. P-LINCS: a parallel linear constraint solver for molecular simulation. J Chem Theory Comput 2008; 4 (01) 116-122
    CrossrefPubMedGoogle Scholar
  • 13 Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graphics 1996; 14 (01) 33-38 , 27–28
    CrossrefPubMedGoogle Scholar
  • 14 Doolittle RF. Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb Symp Quant Biol 2009; 74: 35-40
    CrossrefPubMedGoogle Scholar
  • 15 Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002; 102 (12) 4501-4524
    CrossrefPubMedGoogle Scholar
  • 16 Messier T, Wong C, Bovill E, Long G, Church W. Factor X Stockton: a mild bleeding diathesis associated with an active site mutation in factor X. Blood Coagulation Fibrinolysis 1996; 7 (01) 5-14
    CrossrefPubMedGoogle Scholar
  • 17 Pinotti M, Camire RM, Baroni M, Rajab A, Marchetti G, Bernardi F. Impaired prothrombinase activity of factor X Gly381Asp results in severe familial CRM+ FX deficiency. Thromb Haemost 2003; 89 (02) 243-248
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Abdel-Azeim S, Oliva R, Chermak E, De Cristofaro R, Cavallo L. Molecular dynamics characterization of five pathogenic factor X mutants associated with decreased catalytic activity. Biochemistry 2014; 53 (44) 6992-7001
    CrossrefPubMedGoogle Scholar
  • 19 Millar DS, Elliston L, Deex P. , et al. Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum Genet 2000; 106 (02) 249-257
    CrossrefPubMedGoogle Scholar
  • 20 Venkateswarlu D, Perera L, Darden T, Pedersen LG. Structure and dynamics of zymogen human blood coagulation factor X. Biophys J 2002; 82 (03) 1190-1206
    CrossrefPubMedGoogle Scholar
  • 21 Bode W, Schwager P, Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 A resolution. J Mol Biol 1978; 118 (01) 99-112
    CrossrefPubMedGoogle Scholar
  • 22 Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J Biol Chem 2008; 283 (27) 18627-18635
    CrossrefPubMedGoogle Scholar
  • 23 Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004; 11 (09) 857-862
    CrossrefPubMedGoogle Scholar
  • 24 Banner DW, D'Arcy A, Chène C. , et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380 (6569): 41-46
    CrossrefPubMedGoogle Scholar
  • 25 Johnson DJ, Langdown J, Huntington JA. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proc Natl Acad Sci U S A 2010; 107 (02) 645-650
    CrossrefPubMedGoogle Scholar
  • 26 Navaneetham D, Jin L, Pandey P. , et al. Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem 2005; 280 (43) 36165-36175
    CrossrefPubMedGoogle Scholar
  • 27 Girolami A, Scarparo P, Scandellari R, Allemand E. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol 2008; 83 (08) 668-671
    CrossrefPubMedGoogle Scholar
  • 28 Venkateswarlu D. Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study. Biochem Biophys Res Commun 2014; 452 (03) 408-414
    CrossrefPubMedGoogle Scholar
  • 29 Basu S, Biswas P. Salt-bridge dynamics in intrinsically disordered proteins: a trade-off between electrostatic interactions and structural flexibility. Biochim Biophys Acta Proteins Proteomics 2018; 1866 (5-6): 624-641
    CrossrefPubMedGoogle Scholar
  • 30 Lisgarten DR, Palmer RA, Lobley CMC. , et al. Ultra-high resolution X-ray structures of two forms of human recombinant insulin at 100 K. Chem Cent J 2017; 11 (01) 73
    CrossrefPubMedGoogle Scholar
  • 31 Zhou A, Carrell RW, Murphy MP. , et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010; 468 (7320): 108-111
    PubMedGoogle Scholar